Ameliorative Effects of Schizandra chinensis Extracts and Their Soybean Powder Blends to Diabetes Mellitus

Min Jung Kim¹, Kwang-Hyun Park^{2, 3,} , Hye Jeong Yang^1, , Dai Ja Jang¹, Hak Yong Lee⁴, Young Mi Park⁴, Byeong Soo Kim⁵ and Dong Yeop Shin^{4, 5}

¹Korea Food Research Institute, 245, Wanju, Jeonbuk, 55365, Korea

²BioMedical Science Graduate Program (BMSGP), Chonnam National University, Hwasun, 58128, Korea

³Department of Emergency Medical Rescue, Nambu University, Gwangju, 62271, Korea

⁴INVIVO Co. Ltd., 121, Deahak-ro, Nonsan, Chungnam, 32992, Korea

⁵Department of Integrated Life Science and Technology, Kongju National University, 32439, Korea

Cite this paper:
Min Jung Kim, Kwang-Hyun Park, Hye Jeong Yang, Dai Ja Jang, Hak Yong Lee, Young Mi Park, Byeong Soo Kim and Dong Yeop Shin. Ameliorative Effects of Schizandra chinensis Extracts and Their Soybean Powder Blends to Diabetes Mellitus. Journal of Food and Nutrition Research. 2022; 10(1):8-18. doi: 10.12691/jfnr-10-1-2

Abstract

Schisandrae chinensis (Omija) is traditionally used as a food-based medicinal/pharmaceutical resources including antidiabetic agent in worldwide. In this study, the optimal combined formula of Omija extract and soybean mixture (OSM) were investigated for its effects on type 2 diabetes model expressed in in Vitro and in Vivo animal model. Using whole extracts, we confirmed inhibitory effects to α-glucosidase, α-amylase and the DPPH scavenging in Vitro and examined glucose tolerance in mice. The combined optimum formulation of OSM were significantly ameliorated type 2 diabetes-related. Furthermore, activation of p-Akt, p-AMPK, p-IRS and GLUT2 expression level is pivotal roles of in this anti-diabetic molecular mechanism on in Vivo without side effects. Therefore, these results suggest that OSM is good resources for improves of type 2 diabetes and its complications.

Keywords:
Schisandrae chinensis type 2 diabetes diabetes complication db/db mice antioxidant combined mixture

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Kim, B.H., Cho, D.U., Han, K.S. and Bae, Y.L, “Efficiency analysis of Schisandra tea using image & acoustic signal processing,” Journal of Korea Academia Industrial Cooperation Society 2011; 12: 2975-2981.
[2]	Suh, W.S., Park, S.Y., Min, B.S., Kim, S.H., Song, J.H. and Shim, S.H, “The anti-proliferative effects of compounds isolated from Schisandra chinensis,” Korean Journal of Food Science and Technology 2014; 46: 665-670.
[3]	Jeong, H.S. and Joo, N.M, “Optimization of rheological properties for processing of omija-pyun (omija jelly) by response surface methodology,” Korean Journal of Food and Cookery Science 2003; 19: 429-438.
[4]	Kunyanga, C.N., Imungi, J.K., Okoth, M., Momanyi, C., Biesalski, H.K. and Vadivel, V, “Antioxidant and antidiabetic properties of condensed tannins in acetonic extract of selected raw and processed indigenous food ingredients from Kenya,”. Journal of Food Science. 2011; 76: C560-567.
[5]	Itoh, T., Hori, Y., Atsumi, T., Toriizuka, K., Nakamura, M., Maeyama, T., Ando, M., Tsukamasa, Y., Ida, Y. and Furuichi, Y, “Hot water extract of adzuki (Vigna angularis) suppresses antigen-stimulated degranulation in rat basophilic leukemia RBL-2H3 cells and passive cutaneous anaphylaxis reaction in mice,”. Phytotherapy Research. 2012; 26: 1003-1011.
[6]	Gundermann, K.J., Kuenker, A., Kuntz, E. and Droździk, M, “Activity of essential phospholipids (EPL) from soybean in liver diseases,”. Pharmacological Reports. 2011; 63: 643-659.
[7]	Dixit, A.K., Antony, J.I.X., Sharma, N.K. and Tiwari, R.K, “Soybean constituents and their functional benefits,” Opportunity, Challenge and Scope of Natural Products in Medicinal Chemistry. 2011; 367-383.
[8]	Van Horn, L., McCoin, M., Kris-Etherton, P.M., Burke, F. and Carson, J.A, Champagne, C.M., Karmally, W. and Sikand, G, “The evidence for dietary prevention and treatment of cardiovascular disease,” Journal of the American Dietetic Association. 2008; 108: 287-331.
[9]	Morabito, N., Crisafulli, A., Vergara, C., Gaudio, A., Lasco, A., Frisina, N., D'Anna, R., Corrado, F., Pizzoleo, M.A., Cincotta, M., Altavilla, D., Ientile, R. and Squadrito, F.J, “Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomised double-blind placebo-controlled study,” Journal of Bone and Mineral Research. 2002; 17: 1904-1912.
[10]	Cameron, M., Gagnier, J.J., Little, C.V., Parsons, T.J., Blümle, A. and Chrubasik, S, “Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: Osteoarthritis,” Phytotherapy Research. 2009; 23: 1497-1515.
[11]	Oh, H.G., Kang, Y.R., Lee, H.Y., Kim, J.H., Shin, E.H., Lee, B.G., Park, S.H., Moon, D.I., Kim, O.J., Lee, I.A., Choi, J., Lee, J.E. and Park, K.H. and Suh, J.W, “Ameliorative effects of Monascus pilosus-fermented black soybean (Glycine max L. Merrill) on high-fat diet-induced obesity,” Journal of Medicinal Food. 2014 Sep; 17(9):972-8.
[12]	Baek, S.H, “Prevention of Type 2 diabetes,” Medical Postgraduates. 2007; 3: 128-131.
[13]	James, R, “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care 2003; 26 Supple. 1: S5-20.
[14]	Atkinson, M.A., and Maclaren, N.K, “The pathogenesis of insulin dependent diabetes mellitus,” New England Journal of Medicine 1994; 331: 428-36.
[15]	Wilcox, G, “Insulin and insulin resistance,” Clinical Biochemist Reviews 2005; 26(2): 19-39.
[16]	Singh, N.P., Puqazhendhi, V., Das, A.K., Prakash, A. and Aqarwal, S.K, “Clinical and laboratory profile of diabetes in elderly,” Journal of Indian Medical Association 1999; 97: 124-128.
[17]	Olefsky, J.M., Kolterman, O.G. and Scarlett, J.A, “Insulin action and resistance in obesity and noninsulin-dependent Type II diabetes mellitus,” American Journal of Physiology 1982; 243: E15-30.
[18]	Kaul, K., Hodgkinson, A., Tarr, J.M., Kohner, E.M. and Chibber, R, “Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?,” Current Diabetes Reviews 2010; 6(5): 294-303.
[19]	Rother, K.I. and Harlan, D.M, “Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus,” Journal of Clinical Investigation 2004; 114: 877-83.
[20]	Pandey, A., Tripathi, P., Pandey, R., Srivatava, R. and Goswami, S, “Alternative therapies useful in the management of diabetes: A systematic review,” Journal of Pharmacy and Bioallied Sciences 2011; 3: 504-12.
[21]	Hsieh, M.T., Tsai, M.L., Peng, W.H. and Wu, C.R, “Effects of Schizandrae fructus on cycloheximide-induced amnesia in rats,” Phytotherapy Research 1999; 13: 256-257
[22]	Panossian, A. and Wikman G, “Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine,” Journal of Ethnopharmacology 2008; 118: 183-212.
[23]	Li, Z., He, X., Liu, F., Wang, J. and Feng J, “A review of polysaccharides from Schisandra chinensis and Schisandra sphenanthera: Properties, functions and applications,” Carbohydrate Polymers 2018; 184: 178-190.
[24]	Harsha, C., Banik, K., Bordoloi, D. and Kunnumakkara, A.B, “Antiulcer properties of fruits and vegetables: A mechanism based perspective,” Food and Chemical Toxicology 2017; 108(Pt A): 104-119.
[25]	Zhou, Y., Men, L., Sun, Y., Wei, M. and Fan, X, “Pharmacodynamic effects and molecular mechanisms of lignans from Schisandra chinensis Turcz. (Baill.), a current review,” European Journal of Pharmacology 2021; 892: 173796.
[26]	Nowak, A., Zakłos-Szyda, M., Błasiak, J., Nowak, A., Zhang, Z. and Zhang B, “Potential of Schisandra chinensis (Turcz.) Baill. in Human Health and Nutrition: A Review of Current Knowledge and Schisandra sphenanthera: Properties, functions and applications,” Nutrients, 2019; 11(2), 333.
[27]	Mocan, A., Crișan, G., Vlase, L., Crișan, O., Vodnar, D.., Raita, O., Gheldiu, A.M,, Toiu, A., Oprean, R. and Tilea, I, “Comparative studies on polyphenolic composition, antioxidant and antimicrobial activities of Schisandra chinensis leaves and fruits,” Molecules. 2014; 19: 15162-79.
[28]	Park, C., Hwang, H.J., Choi, B.T., Choi, T.H., Kim, B.W., Choi, Y.W. and Choi, Y.H, “G1 arrest of the cell cycle by gomisin N, a dibenzocyclooctadiene lignan, isolated from Schizandra chinensis Baill in human leukemia U937 cells,” Journal of Life Science 2010; 20: 977-982.
[29]	Kim, J.S. and Choi, S, “Physicochemical properties and antioxidative activities of Omija (Schizandra chinensis Bailon),” The Korean Journal of Food And Nutrition 2008; 21: 35-42.
[30]	Cho, Y.J., Ju, I.S., Kim, B.C., Lee, W.S., Kim, M.J., Lee, B.G., An, B.J., Kim, J.H. and Kwon, O.J, “Biological activity of Omija (Schizandra chinensis Baillon) extracts,” Journal of the Korean Society for Applied Biological Chemistry. 2007; 50: 198-203.
[31]	The Ministry of Health and Medical Industry of Russian Federation, The State Register of Drugs. Official Publication (up to 1st January 2000), Moscow, 2000. pp. 186.
[32]	World Health Organisation, Fructus Schisandrae. WHO Monographs on Selected Medicinal Plants, vol. 3. WHO, Geneva, 2007. pp. 296-313.
[33]	Tibbot, B.K. and Skadsen, R.W, “Molecular cloning and characterization of a gibberellin-inducible, putative α-glucosidase gene from barley,” Plant Molecular Biology 1996; 30: 229-241.
[34]	McCue, P.P. and Shetty, K, “Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase in vitro,” Asia Pacific Journal of Clinical Nutrition 2004; 13: 101-106.
[35]	Desmarchelier, C., Bermudez, M.J.N., Coussio, J., Ciccia, G. and Boveris, A, “Antioxidant and prooxidant activities in aqueous extract of Argentine plants,” International Journal of Pharmacognosy 1997; 35: 116-20.
[36]	Park, K.H., Kim, B.J., Kang, J., Nam, T.S., Lim, J.M., Kim, H.T., Park, J.K., Kim, Y.G., Chae, S.W. and Kim U.H, “Ca2+ signaling tools acquired from prostasomes are required for progesterone-induced sperm motility,” Science Signaling 2011; 4: ra31.
[37]	Park, K.H., Park, D.R.,, Kim, Y.W., Nam, T.S., Jang, K.Y., Chung, H.T. and Kim U.H, “The Essential Role of Ca2+ Signals in UVB-Induced IL-1β Secretion in Keratinocytes,” Journal of Investigative Dermatology 2019; 139: 1362-1372.
[38]	Feldman, E.L., Callaghan, B.C., Pop-Busui, R., Zochodne, D.W., Wright, D.E., Bennett, D.L., Bril, V., Russell, J.W. and Viswanathan, V, “Diabetic neuropathy,” Nature Reviews Disease Primers 2019; 5: 41.
[39]	Ayodele, O.E., Alebiosu, C.O. and Salako, B.L, “Diabetic nephropathy-a review of the natural history, burden, risk factors and treatment,” Journal of the National Medical Association 2004; 96: 1445-54.
[40]	Watkins, P.J, “The diabetic foot,” British Medical Journal (Clinical Research Edition) 2003; 326: 977-9.
[41]	Wong, T.Y., Cheung, C.M., Larsen, M., Sharma, S. and Simó, R, “Diabetic retinopathy,” Nature Reviews Disease Primers 2016; 17: 16012.
[42]	Fowler, M.J, “Microvascular and macrovascular complications of diabetes,” Clinical Diabetes 2008; 26: 77-82.
[43]	Potashner, D., Brown, R.E., Li, A., Riddell, M.C. and Aronson, R, “Paradoxical Rise in Hypoglycemia Symptoms With Development of Hyperglycemia During High-Intensity Interval Training in Type 1 Diabetes,” Diabetes Care. 2019; 42: 2011-2014
[44]	Derosa, G. and Maffioli, P, “Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review,” Clinical Therapeutics 2012; 34: 1221-36.
[45]	DeFronzo, R. and Goodman, A, “Multicenter Metformin Study Group. “Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus,” New England Journal of Medicine 1995; 333: 541-549.